C12N 5/0646
Natural killers cells [nk], nkt cells
Official title: {Natural killers cells [NK], NKT cells}
C12N5/0646 (Natural killers cells [nk], nkt cells) appears on 636 US grants and 1,725 published applications in this corpus.
Search patents in C12N- Granted patents
- 636
- Published applications
- 1,725
- Assignees
- 655
- Inventors
- 2,829
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 1 | 0 |
| 1984 | 2 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 2 | 0 |
| 2000 | 2 | 0 |
| 2001 | 3 | 0 |
| 2002 | 1 | 5 |
| 2003 | 3 | 4 |
| 2004 | 1 | 11 |
| 2005 | 1 | 2 |
| 2006 | 1 | 10 |
| 2007 | 1 | 9 |
| 2008 | 2 | 5 |
| 2009 | 3 | 12 |
| 2010 | 5 | 11 |
| 2011 | 4 | 11 |
| 2012 | 4 | 17 |
| 2013 | 4 | 20 |
| 2014 | 11 | 22 |
| 2015 | 16 | 26 |
| 2016 | 7 | 49 |
| 2017 | 20 | 55 |
| 2018 | 40 | 96 |
| 2019 | 38 | 100 |
| 2020 | 55 | 143 |
| 2021 | 61 | 165 |
| 2022 | 65 | 196 |
| 2023 | 55 | 173 |
| 2024 | 73 | 228 |
| 2025 | 99 | 219 |
| 2026 | 53 | 136 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Immune cells with enhanced cytotoxicity and methods of use thereof29 Sep 2026US 12,747,443 B2Ludwig Institute for Cancer Research
- Chimeric antigen receptors to HER2 and methods of use thereof22 Sep 2026US 12,742,020 B2BioAtla, Inc.
- Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy22 Sep 2026US 12,742,152 B2Angeles Therapeutics, Inc.
- Fixed ratio ex vivo activated mixed lymphocyte products for use in the treatment of cancer22 Sep 2026US 12,742,153 B2Children's National Medical Center
- K562 universal antigen presenting cells and uses thereof15 Sep 2026US 12,734,239 B2Board of Regents, The University of Texas System
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
- Multi-receptor natural killer cells8 Oct 2026US 2026/0308225 A1Board of Regents, The University of Texas System
- Nk cell compositions and preparations for immunotherapy and methods for their production8 Oct 2026US 2026/0308226 A1Deverra Therpaeutics Inc.
- Methods of enhancing or modifying nk cells8 Oct 2026US 2026/0308525 A1Zelluna Immunotherapy AS
- Generation of chimeric antigen receptor (car)-primary nk cells for cancer immunotherapy using a combination of cas9/rnp and aav viruses8 Oct 2026US 2026/0308628 A1Research Institute At Nationwide Children's Hospital
Most cited
By later US patents
- Handheld electromechanical surgical system627US 10,932,784 B2Covidien LP · 2021
- Chimeric receptors with 4-1BB stimulatory signaling domain329US 8,399,645 B2St. Jude Children?S Research Hospital · 2013
- Modified cell line and method for expansion of NK cell123US 7,435,596 B2St. Jude Children?S Research Hospital · 2008
- Ex vivo culture of stem cells105US 5,922,597 ARegents of the University of Minnesota · 1999
- Genetically modified human natural killer cell lines98US 7,618,817 B2Fox Chase Cancer Center · 2009